THE CLINICAL IMPACT OF RIVAROXABAN TO CHINESE AT ATRIAL FIBRILLATION PATIENTS RESULTS FROM A SIMPLE COMMUNICATION TOOL

被引：0
|
作者：
Yang, L. [1 ]
Wu, J. J. [2 ]
Zhu, G. [2 ]
Evers, T. [3 ]
机构：
[1] Peking Univ, Beijing 100871, Peoples R China
[2] Bayer Healthcare Co Ltd, Beijing, Peoples R China
[3] Bayer Pharma AG, Wuppertal, Germany
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCV143
引用
收藏
页码：A497 / A497
页数：1
相关论文
共 50 条
  • [1] THE CLINICAL IMPACT OF RIVAROXABAN TO CHINESE AT DEEP VEIN THROMBOSIS PATIENTS RESULTS FROM A SIMPLE COMMUNICATION TOOL
    Yang, L.
    Wu, J. J.
    Zhu, G.
    Evers, T.
    VALUE IN HEALTH, 2014, 17 (07) : A497 - A498
  • [2] Application of rivaroxaban in clinical practice: results of a prospective observational study XANTUS in patients with atrial fibrillation
    Kanorskii, S. G.
    RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2016, 12 (04) : 443 - 449
  • [3] Net clinical benefit of rivaroxaban compared with warfarin in atrial fibrillation: Results from ROCKET AF
    Barnett, Adam S.
    Cyr, Derek D.
    Goodman, Shaun G.
    Levitan, Bennett S.
    Yuan, Zhong
    Hankey, Graeme J.
    Singer, Daniel E.
    Becker, Richard C.
    Breithardt, Guenter
    Berkowitz, Scott D.
    Halperin, Jonathan L.
    Hacke, Werner
    Mahaffey, Kenneth W.
    Nessel, Christopher C.
    Fox, Keith A. A.
    Patel, Manesh R.
    Piccini, Jonathan P.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2018, 257 : 78 - 83
  • [4] The Efficacy of Rivaroxaban in Patients With Atrial Fibrillation
    Carag, Michael R.
    Arora, Rohit R.
    AMERICAN JOURNAL OF THERAPEUTICS, 2014, 21 (05) : 412 - 418
  • [5] Incidence and predictors of hospitalization in patients with atrial fibrillation: results from the Chinese atrial fibrillation registry study
    Dong, Zhaojie
    Du, Xin
    Lu, Shangxin
    Jiang, Chao
    Xia, Shijun
    He, Liu
    Su, Xin
    Jia, Zhaoxu
    Long, Deyong
    Sang, Caihua
    Tang, Ribo
    Liu, Nian
    Bai, Rong
    Yu, Ronghui
    Dong, Jianzeng
    Ma, Changsheng
    BMC CARDIOVASCULAR DISORDERS, 2021, 21 (01)
  • [6] Incidence and predictors of hospitalization in patients with atrial fibrillation: results from the Chinese atrial fibrillation registry study
    Zhaojie Dong
    Xin Du
    Shangxin Lu
    Chao Jiang
    Shijun Xia
    Liu He
    Xin Su
    Zhaoxu Jia
    Deyong Long
    Caihua Sang
    Ribo Tang
    Nian Liu
    Rong Bai
    Ronghui Yu
    Jianzeng Dong
    Changsheng Ma
    BMC Cardiovascular Disorders, 21
  • [7] Clinical Safety Outcomes in Patients With Nonvalvular Atrial Fibrillation on Rivaroxaban and Diltiazem
    Bartlett, Jenna W.
    Renner, Elizabeth
    Mouland, Erin
    Barnes, Geoffrey D.
    Kuo, Liane
    Ha, Nghi B.
    ANNALS OF PHARMACOTHERAPY, 2019, 53 (01) : 21 - 27
  • [8] Drug Persistence with Rivaroxaban Therapy in Atrial Fibrillation Patients Results from the Dresden NOAC registry
    Beyer-Westendorf, Jan
    Foerster, Kati
    Ebertz, Franziska
    Gelbricht, Vera
    Michalski, Franziska
    Tittl, Luise
    Weiss, Norbert
    BLOOD, 2014, 124 (21)
  • [9] Net clinical benefit of rivaroxaban compared with warfarin in patients with atrial fibrillation
    Piccini, J.
    Goodman, S.
    Levitan, B.
    Yuan, Z.
    Hankey, G. J.
    Singer, D. E.
    Becker, R.
    Breithardt, G.
    Berkowitz, S.
    Halperin, J.
    Nessel, C.
    Hacke, W.
    Mahaffey, K. W.
    Fox, K. A. A.
    Patel, M. R.
    EUROPEAN HEART JOURNAL, 2016, 37 : 500 - 500
  • [10] Clinical efficacy of rivaroxaban and Warfarin in patients with atrial fibrillation complicated with left atrial thrombosis
    吕程
    ChinaMedicalAbstracts(InternalMedicine), 2017, 34 (01) : 33 - 33
12345